1. Tesamorelin, (formerly known as TH9507), is a type of peptide called a -releasing factor (GHRF). GHRF causes to be created and spread in the body, which helps increase metabolism, reduce belly fat, improve body shape, and use of energy.

2. Tesamorelin (formerly known as TH9507) is a synthetic-releasing factor that stimulates the pituitary gland in the brain to secrete ; this indirect approach appears to maintain more stable, natural levels, like CJC-1295 DAC,.

3. Clinical trials have shown that tesamorelin significantly reduces abdominal fat with fewer side effects than human growth hormone itself, although abdominal fat may return after the Tesamorlein is discontinued (depending upon the individual).

4. Tesamorelin has been shown to reduce lipodystrophy in HIV-infected individuals as well as similarly reducing abdominal fat in NON-HIV-Infected individuals.

5. Tesamorelin has been shown to reduce lipodystrophy in HIV-infected individuals. Lipodystrophy is a condition that causes changes in placement of body fat, including wasting and fat accumulation, and changes in metabolism.

6. Similar to Tesamorelin is Sermorelin, which may be taken with GHRP-6 is clinical trials, that also promotes production and possible fat loss. Individuals with lipodystrophy may develop excess fat most notably around the liver, stomach, and other abdominal organs (visceral body fat).

7. Tesamorelin is a synthetic peptide consisting of all 44 amino acids of hGRF with the addition of a trans-3-Hexenoic acid group.

8. Tesamorelin (also known as Egrifta) is a synthetic form which is used in the treatment of HIV-associated lipodystrophy.

9. Tesamorelin has been shown to reduce lipodystrophy in HIV-infected individuals. Lipodystrophy is a condition that causes changes in placement of body fat, including wasting and fat accumulation, and changes in metabolism.

10. Similar to Tesamorelin is Sermorelin, which may be taken with GHRP-6 is clinical trials, that also promotes production and possible fat loss. Individuals with lipodystrophy may develop excess fat most notably around the liver, stomach, and other abdominal organs (visceral body fat).